AMGEN INC

Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers innovative medicines to combat some of the world's toughest diseases. The company's business strategy focuses on areas of high unmet medical need and leverages its expertise to make a significant difference for patients suffering from serious diseases. Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. It operates in one business segment: human therapeutics. Amgen's significant developments include the acquisition of Horizon Therapeutics plc in October 2023, which added first-in-class, early-in-lifecycle medicines to Amgen's rare disease portfolio. The company also has a robust pipeline of potential first-in-class medicines at all stages of development. Amgen markets its products around the world, with the United States as its largest market. Its products include Prolia, ENBREL, Otezla, XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, KRYSTEXXA, and other marketed products. The company also has a significant number of patents for its products, including those for Prolia, Enbrel, Otezla, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, BLINCYTO, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, KRYSTEXXA, TAVNEOS, UPLIZNA, and PROCYSBI. Amgen operates in a highly competitive environment, with competition coming from both branded and biosimilar versions of its products. The company faces competition from various competitors, including AbbVie, Novartis, Lilly, Janssen, Pfizer, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals, Inc., and Sanofi, among others. Amgen's website is www.amgen.com, and its ticker symbol is AMGN.